Corpus ID: 201613281

Bmi-1 serves as a potential novel marker for progression in human cutaneous basal cell carcinoma.

  title={Bmi-1 serves as a potential novel marker for progression in human cutaneous basal cell carcinoma.},
  author={Hongyan Zhu and Jian Wu and Xiaomei Cui and Xiaodong Chen},
  journal={International journal of clinical and experimental pathology},
  volume={10 8},
B-cell-specific Moloney murine leukemia virus integration site 1 (Bmi-1) is one of the core members of the PRC1 complex (the polycomb gene family) involved in tumorigenesis. The aim of this study is to investigate the expression and possible function of Bmi-1 in cutaneous basal cell carcinoma (BCC). Here, by immunohistochemical staining, we found that elevated Bmi-1 expression was more commonly observed in fresh BCC tissues compared with normal. Bmi-1 RNAi revealed that suppression of… Expand
Circular RNA hsa_Circ_0005795 mediates cell proliferation of cutaneous basal cell carcinoma via sponging miR-1231
Knockdown of Circ_0005795 dramatically reduced cell viability, colony formation, and anti-apoptotic protein levels, while increased caspase-3 activity, and worked as an oncogene in BCC. Expand


Loss of BMI-1 expression is associated with clinical progress of malignant melanoma
In established melanomas, loss of BMI-1 expression was associated with features of aggressive tumors, such as increased tumor cell proliferation, presence of necrosis and increased expression of both N-cadherin and β3-integrin, indicating a more invasive and mesenchymal phenotype. Expand
Oncoprotein BMI‐1 induces the malignant transformation of HaCaT cells
It is demonstrated that dysregulated BMI‐1 could indeed lead to keratinocytes transformation and tumorigenesis, potentially through promoting cell cycle progression and increasing cell mobility. Expand
Expression of Bmi-1 in epidermis enhances cell survival by altering cell cycle regulatory protein expression and inhibiting apoptosis.
It is proposed that Bmi-1 may promote maintenance of suprabasal keratinocyte survival to prevent premature death during differentiation and help assure proper formation of the stratified epidermis. Expand
Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells.
This study provides the first cellular proto-oncogene immortalized nasopharyngeal epithelial cell line, which may serve as a cell model system for studying the mechanisms involved in the tumorigenesis of nasopharygeal carcinoma. Expand
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells.
It is found that upregulation of Bmi-1 induced epithelial-mesenchymal transition (EMT) and enhanced the motility and invasiveness of human nasopharyngeal epithelial cells, whereas silencing endogenous Bmi -1 expression reversed EMT and reduced motility. Expand
Bmi-1-shRNA inhibits the proliferation of lung adenocarcinoma cells by blocking the G1/S phase through decreasing cyclin D1 and increasing p21/p27 levels.
Data indicate that Bmi-1 might modulate the growth of lung adenocarcinoma cells in an INK4a-p16 independent pathway. Expand
Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer
It is demonstrated that silencing Bmi-1 reduces intracellular GSH levels and thereby sensitizes chemoresistant ovarian cancer cells to chemotherapeutics such as cisplatin. Expand
Bmi-1, stem cells and cancer.
The function of Bmi-1 is summarized as a transcriptional regulator of gene expression, with particular reference to stem cells, in the present review. Expand
The role of polycomb group protein Bmi-1 and Notch4 in breast cancer stem cell inhibition by benzyl isothiocyanate
Important roles for Bmi-1 and Notch4 in BITC-mediated suppression of bCSC are highlighted, which were previously shown to cause activation of Notch1, Notch2, and NotCh4 in association with induction of γ-secretase complex component Nicastrin. Expand
Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
  • J. Lear
  • Medicine
  • The New England journal of medicine
  • 2012
Basal-cell carcinoma of the skin is the most common cancer worldwide, and its prevalence is increasing, accounting for 80% of nonmelanoma skin cancers.1 In 2006, more than 2.1 million new cases ofExpand